0001790340-24-000034.txt : 20240321 0001790340-24-000034.hdr.sgml : 20240321 20240321090610 ACCESSION NUMBER: 0001790340-24-000034 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240315 FILED AS OF DATE: 20240321 DATE AS OF CHANGE: 20240321 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hall Brett Matthew CENTRAL INDEX KEY: 0001870437 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40675 FILM NUMBER: 24769676 MAIL ADDRESS: STREET 1: C/O IMMUNEERING CORPORATION STREET 2: 245 MAIN STREET, SECOND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Immuneering Corp CENTRAL INDEX KEY: 0001790340 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 245 MAIN STREET, SECOND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-500-8080 MAIL ADDRESS: STREET 1: 245 MAIN STREET, SECOND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 wk-form4_1711026361.xml FORM 4 X0508 4 2024-03-15 0 0001790340 Immuneering Corp IMRX 0001870437 Hall Brett Matthew 245 MAIN STREET SECOND FLOOR CAMBRIDGE MA 02142 0 1 0 0 CHIEF SCIENTIFIC OFFICER 0 Class A Common Stock 2024-03-15 4 A 0 6211 1.62 A 338896 D Class A Common Stock 2024-03-20 4 P 0 7000 2.86 A 345896 D The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of September 15, 2023 through March 15, 2024. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934. The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of March 15, 2024. In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Purchase Date of March 15, 2024. /s/ Michael D. Bookman, Attorney-in-Fact for Brett Matthew Hall 2024-03-21